Nicole E. Caston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nicole E. Caston has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Gabrielle Betty Rocque
O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL
18 shared publications - Stephanie Brooke Wheeler
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina
8 shared publications - Andres Azuero
School of Nursing, University of Alabama at Birmingham , Birmingham, AL
7 shared publications - Austin R. Waters
Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
7 shared publications - Courtney P. Williams
University of Alabama at Birmingham, Birmingham, AL
7 shared publications - Lisa P. Spees
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
7 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Patterns of Enrollment of Traditionally Underrepresented Patients in ECOG-ACRIN Sponsored Breast Cancer Therapeutic Clinical Trials
Introduction: Cancer clinical trials do not always represent the real-world cancer population, as older adults and marginalized racial groups are often underrepresented. This study assessed patterns of enrollment of underrepresented patients and how trial and site factors may influence enrollment. Methods: This retrospective, pooled cross-sectional study used de-identified data from ECOG-ACRIN (EA)-sponsored breast cancer therapeutic clinical trials from 2002-2020. Patient- and trial-level data were extracted from EA trials and ClinicalTrials.gov . Site-level data were from de-identified Landscape Assessment surveys voluntarily completed by National Cancer Institute Community Oncology Research Program sites. Outcomes included the proportions of underrepresented patients enrolled on a trial. Fractional regression models evaluated associations between trial-level factors and enrollment proportions of underrepresented patients using adjusted means and 95% confidence intervals (CI). Weighted Kappa (Kw) statistics and corresponding 95% CI estimated the level of agreement between patient populations served by sites versus enrolled on a trial. Results: Of 9,015 patients enrolled across 12 trials, 18% were aged ≥65 years old, 12% were Black, 15% were Medicare beneficiaries, and 15% were rural residents (unadjusted enrollment). Adjusted mean proportion enrollment of underrepresented patients was similar to unadjusted results. Over half of trials were randomized and 92% of studies had two or more drugs in the protocol, yet these did not appear to influence mean enrollment of underrepresented groups. Moderate levels of agreement were found between Black patients served versus enrolled (Kw 0.64; 95% CI 0.50-0.78), and low or no agreement for Medicare beneficiaries and patients aged ≥65 (Kw 0.18, 0.05-0.31; Kw 0.02, -0.06-0.11; respectively). Conclusions: EA-sponsored breast trials continue to enroll few individuals from underrepresented backgrounds. Trial design had a minimal impact on enrollment and patient populations sites served did not typically match the patients enrolled on trials. More research is needed to engage sites and test strategies for enrolling underrepresented patients.
- 19 February 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Open AccessPatterns of Enrollment of Traditionally Underrepresented Patients in ECOG-ACRIN Sponsored Breast Cancer Therapeutic Clinical Trials
Introduction: Cancer clinical trials do not always represent the real-world cancer population, as older adults and marginalized racial groups are often underrepresented. This study assessed patterns of enrollment of underrepresented patients and how trial and site factors may influence enrollment. Methods: This retrospective, pooled cross-sectional study used de-identified data from ECOG-ACRIN (EA)-sponsored breast cancer therapeutic clinical trials from 2002-2020. Patient- and trial-level data were extracted from EA trials and ClinicalTrials.gov . Site-level data were from de-identified Landscape Assessment surveys voluntarily completed by National Cancer Institute Community Oncology Research Program sites. Outcomes included the proportions of underrepresented patients enrolled on a trial. Fractional regression models evaluated associations between trial-level factors and enrollment proportions of underrepresented patients using adjusted means and 95% confidence intervals (CI). Weighted Kappa (Kw) statistics and corresponding 95% CI estimated the level of agreement between patient populations served by sites versus enrolled on a trial. Results: Of 9,015 patients enrolled across 12 trials, 18% were aged ≥65 years old, 12% were Black, 15% were Medicare beneficiaries, and 15% were rural residents (unadjusted enrollment). Adjusted mean proportion enrollment of underrepresented patients was similar to unadjusted results. Over half of trials were randomized and 92% of studies had two or more drugs in the protocol, yet these did not appear to influence mean enrollment of underrepresented groups. Moderate levels of agreement were found between Black patients served versus enrolled (Kw 0.64; 95% CI 0.50-0.78), and low or no agreement for Medicare beneficiaries and patients aged ≥65 (Kw 0.18, 0.05-0.31; Kw 0.02, -0.06-0.11; respectively). Conclusions: EA-sponsored breast trials continue to enroll few individuals from underrepresented backgrounds. Trial design had a minimal impact on enrollment and patient populations sites served did not typically match the patients enrolled on trials. More research is needed to engage sites and test strategies for enrolling underrepresented patients.
- Open Access
- 31 January 2026
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
Trends in End-of-Life Care Quality Among Patients With Cancer, 2003 to 2019
Background: As cancer remains a leading cause of death for older adults, ensuring high-quality end-of-life (EOL) care is a critical component of cancer care. Prior studies have predominantly assessed EOL care for racial and ethnic disparities or among one cancer type. Therefore, using a population-based sample, our objective was to describe EOL care among decedents with cancer across various social and clinical characteristics. Methods: This retrospective cohort study used 2003-2019 data from The University of North Carolina at Chapel Hill Cancer Information and Population Health Resource, which links cancer registry to administrative claims data in North Carolina. We examined five EOL practices within the last 30 days of life including: >1 emergency department (ED) visit, intensive care unit (ICU) admission, hospital admission, intravenous (IV) chemotherapy, and no hospice use. We assessed in-hospital death and late hospice initiation in the last 3 days of life. We descriptively assessed differences in EOL by various demographic characteristics. Results: Among 150 412 decedents, 48% were female, 23% were non-Hispanic Black, and 61% were Medicare beneficiaries. The most frequent EOL care practice was hospital admission (54%). Over time, no hospice use, ICU admission, hospital admissions, and in-hospital deaths decreased. However, in 2019, hospital admissions and no hospice use were still high (52% & 38%, respectively). Compared to patients with other insurance, Medicaid decedents had the best quality EOL care: ED visit (9%), hospital admission (45%), and hospice initiation in the last 3 days (6%). Conclusions: Additional research is needed to understand what could be driving these observed differences. Interventions, such as EOL patient navigation, could improve upon EOL care in patients with cancer.
- 31 January 2026
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
Open AccessTrends in End-of-Life Care Quality Among Patients With Cancer, 2003 to 2019
Background: As cancer remains a leading cause of death for older adults, ensuring high-quality end-of-life (EOL) care is a critical component of cancer care. Prior studies have predominantly assessed EOL care for racial and ethnic disparities or among one cancer type. Therefore, using a population-based sample, our objective was to describe EOL care among decedents with cancer across various social and clinical characteristics. Methods: This retrospective cohort study used 2003-2019 data from The University of North Carolina at Chapel Hill Cancer Information and Population Health Resource, which links cancer registry to administrative claims data in North Carolina. We examined five EOL practices within the last 30 days of life including: >1 emergency department (ED) visit, intensive care unit (ICU) admission, hospital admission, intravenous (IV) chemotherapy, and no hospice use. We assessed in-hospital death and late hospice initiation in the last 3 days of life. We descriptively assessed differences in EOL by various demographic characteristics. Results: Among 150 412 decedents, 48% were female, 23% were non-Hispanic Black, and 61% were Medicare beneficiaries. The most frequent EOL care practice was hospital admission (54%). Over time, no hospice use, ICU admission, hospital admissions, and in-hospital deaths decreased. However, in 2019, hospital admissions and no hospice use were still high (52% & 38%, respectively). Compared to patients with other insurance, Medicaid decedents had the best quality EOL care: ED visit (9%), hospital admission (45%), and hospice initiation in the last 3 days (6%). Conclusions: Additional research is needed to understand what could be driving these observed differences. Interventions, such as EOL patient navigation, could improve upon EOL care in patients with cancer.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Supplementary Table S2 contains demographics of individuals in the sensitivity analysis.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Supplementary Table S2 contains demographics of individuals in the sensitivity analysis.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Supplementary Table S1 contains demographics on individuals included vs excluded in the manuscript.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Supplementary Table S1 contains demographics on individuals included vs excluded in the manuscript.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Supplementary Table S3 contains model results from the sensitivity analysis.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Supplementary Table S3 contains model results from the sensitivity analysis.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Background:Varying mammography guidelines can serve as a barrier to care. It is unknown how financial hardship, insurance, and rurality are associated with mammography receipt.Methods:This cross-sectional study used 2023 National Health Interview Survey data. Outcomes included receipt of an American Cancer Society (ACS) or US Preventive Services Task Force (USPSTF) guideline-concordant mammogram. Exposures included report of healthcare-related financial hardship (HRFH), insurance status, and rurality. We estimated ORs and 95% confidence intervals (CI) to assess the interaction between (1) HRFH and insurance status and (2) HRFH and rurality on receipt of an ACS or USPSTF mammogram.Results:A total of 11,138 women were included who were eligible to receive a mammogram based on USPSTF guidelines. The mean age was 51 years, 61% were non-Hispanic White, 10% lived in poverty, and 19% had not received a USPSTF guideline–concordant mammogram. We found that among insured individuals, those who did vs did not report HRFH had lower odds of receipt of a USPSTF guideline–concordant mammogram (OR, 0.68; 95% CI, 0.58–0.80). Additionally, we found that among urban residents, those who did vs did not report HRFH had lower odds of receipt of an USPSTF guideline–concordant mammogram (OR, 0.68; 95% CI, 0.58–0.79). The results were similar assessing the receipt of an ACS guideline–concordant mammogram.Conclusions:Financial hardship is a barrier to mammography regardless of insurance status and rural residence.Impact:Programs that address financial barriers to cancer screening beyond insurance and rural access are needed.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Background:Varying mammography guidelines can serve as a barrier to care. It is unknown how financial hardship, insurance, and rurality are associated with mammography receipt.Methods:This cross-sectional study used 2023 National Health Interview Survey data. Outcomes included receipt of an American Cancer Society (ACS) or US Preventive Services Task Force (USPSTF) guideline-concordant mammogram. Exposures included report of healthcare-related financial hardship (HRFH), insurance status, and rurality. We estimated ORs and 95% confidence intervals (CI) to assess the interaction between (1) HRFH and insurance status and (2) HRFH and rurality on receipt of an ACS or USPSTF mammogram.Results:A total of 11,138 women were included who were eligible to receive a mammogram based on USPSTF guidelines. The mean age was 51 years, 61% were non-Hispanic White, 10% lived in poverty, and 19% had not received a USPSTF guideline–concordant mammogram. We found that among insured individuals, those who did vs did not report HRFH had lower odds of receipt of a USPSTF guideline–concordant mammogram (OR, 0.68; 95% CI, 0.58–0.80). Additionally, we found that among urban residents, those who did vs did not report HRFH had lower odds of receipt of an USPSTF guideline–concordant mammogram (OR, 0.68; 95% CI, 0.58–0.79). The results were similar assessing the receipt of an ACS guideline–concordant mammogram.Conclusions:Financial hardship is a barrier to mammography regardless of insurance status and rural residence.Impact:Programs that address financial barriers to cancer screening beyond insurance and rural access are needed.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supp Materials & Methods from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
This file contains supplementary materials and methods describing how the outcome variable was created.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Materials & Methods from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
This file contains supplementary materials and methods describing how the outcome variable was created.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Supplementary Figure S1 shows predicted probabilities of the sensitivity analysis.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Supplementary Figure S1 shows predicted probabilities of the sensitivity analysis.
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (12) , 2150-2157
Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Background: Varying mammography guidelines can serve as a barrier to care. It is unknown how financial hardship, insurance, and rurality are associated with mammography receipt. Methods: This cross-sectional study used 2023 National Health Interview Survey data. Outcomes included receipt of an American Cancer Society (ACS) or US Preventive Services Task Force (USPSTF) guideline-concordant mammogram. Exposures included report of healthcare-related financial hardship (HRFH), insurance status, and rurality. We estimated ORs and 95% confidence intervals (CI) to assess the interaction between (1) HRFH and insurance status and (2) HRFH and rurality on receipt of an ACS or USPSTF mammogram. Results: A total of 11,138 women were included who were eligible to receive a mammogram based on USPSTF guidelines. The mean age was 51 years, 61% were non-Hispanic White, 10% lived in poverty, and 19% had not received a USPSTF guideline–concordant mammogram. We found that among insured individuals, those who did vs did not report HRFH had lower odds of receipt of a USPSTF guideline–concordant mammogram (OR, 0.68; 95% CI, 0.58–0.80). Additionally, we found that among urban residents, those who did vs did not report HRFH had lower odds of receipt of an USPSTF guideline–concordant mammogram (OR, 0.68; 95% CI, 0.58–0.79). The results were similar assessing the receipt of an ACS guideline–concordant mammogram. Conclusions: Financial hardship is a barrier to mammography regardless of insurance status and rural residence. Impact: Programs that address financial barriers to cancer screening beyond insurance and rural access are needed.
- 29 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (12) , 2150-2157
Open AccessAssociations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography
Background: Varying mammography guidelines can serve as a barrier to care. It is unknown how financial hardship, insurance, and rurality are associated with mammography receipt. Methods: This cross-sectional study used 2023 National Health Interview Survey data. Outcomes included receipt of an American Cancer Society (ACS) or US Preventive Services Task Force (USPSTF) guideline-concordant mammogram. Exposures included report of healthcare-related financial hardship (HRFH), insurance status, and rurality. We estimated ORs and 95% confidence intervals (CI) to assess the interaction between (1) HRFH and insurance status and (2) HRFH and rurality on receipt of an ACS or USPSTF mammogram. Results: A total of 11,138 women were included who were eligible to receive a mammogram based on USPSTF guidelines. The mean age was 51 years, 61% were non-Hispanic White, 10% lived in poverty, and 19% had not received a USPSTF guideline–concordant mammogram. We found that among insured individuals, those who did vs did not report HRFH had lower odds of receipt of a USPSTF guideline–concordant mammogram (OR, 0.68; 95% CI, 0.58–0.80). Additionally, we found that among urban residents, those who did vs did not report HRFH had lower odds of receipt of an USPSTF guideline–concordant mammogram (OR, 0.68; 95% CI, 0.58–0.79). The results were similar assessing the receipt of an ACS guideline–concordant mammogram. Conclusions: Financial hardship is a barrier to mammography regardless of insurance status and rural residence. Impact: Programs that address financial barriers to cancer screening beyond insurance and rural access are needed.
- 13 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (10) , OP2400736-1511
System-Level Transformations to Increase Patient Participation in Clinical Trials
PURPOSE: Over the course of the COVID-19 pandemic, the Food and Drug Administration allowed cancer clinical trials to make modifications. As policymakers consider sustaining these modifications, understanding patient perspectives on impact is critical. METHODS: This cross-sectional study used survey data collected between August 2021 and September 2021 by the Translational Breast Cancer Research Consortium and December 2022 by Patient Advocate Foundation among female breast cancer survivors. Respondents reported how changes to location, telemedicine, convenience, and opting out of certain procedures would affect their willingness to participate in a trial. Respondents' county-level vulnerability was determined using five-digit Federal Information Processing Standard codes to link to the Social Vulnerability Index (SVI) overall theme (range, 0-1). According to the SVI, the most vulnerable counties are those in the upper 10% of the overall theme. Model-estimated odds ratios (ORs) and 95% CIs were estimated using multinomial logistic regression models to explore the association between county-level social vulnerability and willingness to participate. RESULTS: Overall, 573 women were included, 12% lived in the most vulnerable counties, and 18% had previous trial participation. Over half (53%) reported that they would be very willing to participate in a trial that offered medication delivery to the home. When compared with all other counties, respondents in most vulnerable counties did not have increased willingness to participate in a trial using telemedicine (OR, 0.21 [95% CI, 0.07 to 0.63]). Results were similar for all other trial modifications, though not statistically significant. CONCLUSION: Our sample of breast cancer survivors viewed trial modifications favorably. However, respondents in the most vulnerable counties were less likely to be influenced by these modifications. Research is needed to understand if additional modifications would influence participation of this vulnerable population.
- 13 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (10) , OP2400736-1511
System-Level Transformations to Increase Patient Participation in Clinical Trials
PURPOSE: Over the course of the COVID-19 pandemic, the Food and Drug Administration allowed cancer clinical trials to make modifications. As policymakers consider sustaining these modifications, understanding patient perspectives on impact is critical. METHODS: This cross-sectional study used survey data collected between August 2021 and September 2021 by the Translational Breast Cancer Research Consortium and December 2022 by Patient Advocate Foundation among female breast cancer survivors. Respondents reported how changes to location, telemedicine, convenience, and opting out of certain procedures would affect their willingness to participate in a trial. Respondents' county-level vulnerability was determined using five-digit Federal Information Processing Standard codes to link to the Social Vulnerability Index (SVI) overall theme (range, 0-1). According to the SVI, the most vulnerable counties are those in the upper 10% of the overall theme. Model-estimated odds ratios (ORs) and 95% CIs were estimated using multinomial logistic regression models to explore the association between county-level social vulnerability and willingness to participate. RESULTS: Overall, 573 women were included, 12% lived in the most vulnerable counties, and 18% had previous trial participation. Over half (53%) reported that they would be very willing to participate in a trial that offered medication delivery to the home. When compared with all other counties, respondents in most vulnerable counties did not have increased willingness to participate in a trial using telemedicine (OR, 0.21 [95% CI, 0.07 to 0.63]). Results were similar for all other trial modifications, though not statistically significant. CONCLUSION: Our sample of breast cancer survivors viewed trial modifications favorably. However, respondents in the most vulnerable counties were less likely to be influenced by these modifications. Research is needed to understand if additional modifications would influence participation of this vulnerable population.